Anti-Human CD30/TNFRSF8 & CD16a/FCGR3A Bispecific Reference Antibody (Acimtamig, RUO)

Description: Acimtamig (BS12128) is a research-grade recombinant antibody targeting CD30L. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgGVH-V-kappa-VH'-V-lambdahomodimer
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD30Lreceptor,Ki-1antigen,CD30,TNFRSF8,D1S166E,Tumornecrosisfactorreceptorsuperfamilymember8,LymphocyteactivationantigenCD30,CD16a,CD16A,FCGR3A,Fc-gammaRIII-alpha,FcRIIIa,IgGFcreceptorIII-2,LowaffinityimmunoglobulingammaFcregionreceptorIII-A,IGFR3,CD16aantigen,Fc-gammaRIII,FCGR3,Fc-gammaRIIIa,FCG3,FcRIII,FcR-10
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:2738880-26-5
Background: Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL).
Note: For research use only. Not suitable for clinical or therapeutic use.